Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. [electronic resource]
Producer: 20000817Description: 381-6 p. digitalISSN:- 0735-1097
- Abciximab
- Aged
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal -- adverse effects
- Female
- Humans
- Immunoglobulin Fab Fragments -- adverse effects
- Male
- Middle Aged
- Myocardial Infarction -- drug therapy
- Platelet Aggregation Inhibitors -- adverse effects
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Randomized Controlled Trials as Topic
- Sex Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.